Feb 13, 2017
Fast Company Honors Braeburn Pharmaceuticals as a Top Ten Most Innovative Company in Biotech
PRINCETON, N.J., Feb. 13, 2017 /PRNewswire/ -- Braeburn Pharmaceuticals was named today by Fast Company as a Top 10 Most Innovative Company in Biotech in conjunction with its annual ranking of the world's 50 Most Innovative Companies for 2017. Previous honorees in the top 10 most innovative biotech companies include Bristol-Myers Squibb, Amgen, and 23andMe.
Braeburn's mission is to develop and deliver individualized, long-acting medicines to patients that suffer from serious, stigmatized neuropsychiatric disorders such as opioid addiction, chronic pain, and schizophrenia. In May 2016, Braeburn's Probuphine® received FDA approval and became the first buprenorphine implant for the long-term maintenance treatment of opioid addiction. This year Braeburn plans to file a new drug application (NDA) for a weekly and monthly injectable buprenorphine for the treatment of opioid dependence, and to progress a six-month risperidone implant for the treatment of schizophrenia.
"The team at Braeburn Pharmaceuticals is focused on bringing cutting-edge innovations to underserved patient populations," said Behshad Sheldon, President and CEO of Braeburn Pharmaceuticals. "We developed our pipeline strategically to include long-acting injectable and implantable formulations that ensure patients can receive the optimal dose of medication on a continuous, long-term basis. This past year our team accomplished so much, but considering the epidemic scale of opioid addiction in the U.S. alone, our mission remains critical; the potential benefit of our work has never been more apparent."
Most Innovative Companies is one of Fast Company's most significant and highly-anticipated editorial efforts of the year. To produce the 2017 list, Fast Company surveyed thousands of enterprises across the globe to identify the most notable innovations of the year and trace the impact of those initiatives on business, industry, and the larger culture.
"Each year, our reporting team scours the globe to identify organizations that have been both innovative and impactful in their industry, the business world, and the larger culture," said Robert Safian, Editor, Fast Company. "At a time marked by political and economic uncertainty, your ability to rise to the top of your field is especially meaningful and inspiring. I'm excited to welcome you to a dynamic inspiring class of companies from around the world."
Fast Company's Most Innovative Companies issue (March 2017) is now available online at www.fastcompany.com/MIC as well as in app form via iTunes, and on newsstands beginning February 21.
ABOUT FAST COMPANY
Fast Company is the world's leading progressive business media brand, with a unique editorial focus on innovation in technology, ethical economics, leadership, and design. Headquartered in New York City, Fast Company is published by Mansueto Ventures LLC, one of the U.S.'s leading media companies.
About Braeburn Pharmaceuticals
Braeburn Pharmaceuticals, an Apple Tree Partners company, is a commercial-stage pharmaceutical company delivering individualized medicine in neuroscience. Long-acting therapeutic treatment options can be essential to improving patient outcomes and facilitating recovery in neurological and psychiatric disorders, which are often complicated by stigma and present significant public health challenges. Braeburn's commercial product, Probuphine® (buprenorphine) implant was approved by the FDA in May 2016. Braeburn's investigational product pipeline consists of long-acting implantable and injectable therapies for serious neurological and psychiatric disorders, including opioid addiction, pain, and schizophrenia. Braeburn's pipeline products are at various stages of clinical development and include weekly and monthly CAM2038, subcutaneous injection depot formulations of buprenorphine, being investigated in opioid addiction and pain, BB0417 buprenorphine/granisetron injectable for acute pain, and BB0817, six-month risperidone implant being investigated in schizophrenia. More information on Braeburn can be found at www.braeburnpharmaceuticals.com.